MIRM8:00 AMMirum Pharmaceuticals Announces Primary Endpoint Met in Phase 2b Portion of the AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta VirusTrial Results • Phase 2mirumpharma.com